ID
45506
Descripción
Principal Investigator: Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488 Lung carcinoma is the leading cause of cancer death in the United States and world-wide; lung adenocarcinoma is the most common cause of lung cancer. Pilot studies of lung adenocarcinoma with hybrid-capture based whole exome sequencing will enable us to identify new targets for therapy and improve diagnosis. We will analyze a blend of whole exome and whole genome sequencing data as well as copy number and somatic mutation calls for 200 tumor and matched normal controls. When completed this study will represent the most comprehensive lung adenocarcinoma genome dataset to date.
Link
Palabras clave
Versiones (2)
- 9/11/22 9/11/22 - Dr. med. Lucy Kessler
- 13/12/22 13/12/22 - Kristina Keller
Titular de derechos de autor
Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA
Subido en
13 de diciembre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000488 Genomic Sequencing of Lung Adenocarcinoma
Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
Similar models
Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
C0728940 (UMLS CUI [1,2])
C2699638 (UMLS CUI [1,2])
C0678257 (UMLS CUI [1,2])
C0919553 (UMLS CUI [2,1])
C0936012 (UMLS CUI [1,2])
C1704324 (UMLS CUI [1,3])